Arcturus Therapeutics shares are trading higher after the company announced a strategic collaboration with Thermo Fisher Scientific to help
Arcturus Therapeutics shares are trading higher after the company announced a strategic collaboration with Thermo Fisher Scientific to help support the Phase 3 development and potential commercialization of ARCT-032. Also, Freedom Broker initiated its coverage on the stock with a Buy rating and announced a price target of $27.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.